Par Pharma suit + IMS ruling = off-label showdown?

Par Pharmaceuticals' ($PRX) free speech lawsuit against the FDA--coupled with recent Supreme Court action--could prompt a court battle over off-label marketing. "Par's going to blow it wide open," the Coalition for Healthcare Communication's John Kamp tells Medical Marketing & Media. Report

Suggested Articles

Astellas and Seattle Genetics are out with Padcev-Keytruda combo data that may be good enough to snag an expedited regulatory review, analysts say.

Distributors had offered billions of dollars to wrap up opioid litigation, but that effort has suffered a major setback, WSJ reports.

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.